Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223353 | 1.00 | MMP1 (0.33) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL4698912 | 0.91 | ANPEP (0.33) | ANPEPENPEP | |
| SCHEMBL915023 | 0.91 | ANPEP (0.33) | ANPEPENPEP | |
| SCHEMBL2973374 | 0.89 | ANPEP (0.31) | ANPEPENPEP | |
| SCHEMBL8222633 | 0.89 | ANPEP (0.31) | ANPEPENPEP | |
| SCHEMBL916297 | 0.87 | ANPEP (0.33) | ANPEPENPEP | |
| SCHEMBL4700722 | 0.87 | ANPEP (0.33) | ANPEPENPEP | |
| SCHEMBL4698308 | 0.86 | ANPEP (0.33) | ANPEPENPEP | |
| SCHEMBL915841 | 0.86 | ANPEP (0.33) | ANPEPENPEP | |
| SCHEMBL3255171 | 0.83 | MMP1 (0.37) | MMP1MMP2MMP3MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919859-B1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID AND USE | XENOPORT INC (US) | 2010-06-02 | — | — | EP | claimed |
| US-7351740-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2008-04-01 | — | — | US | claimed |
| US-20070027210-A1 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. | 2007-02-01 | — | — | US | claimed |
| US-8372881-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| WO-2011028234-A1 | USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID | XENOPORT, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110060040-A1 | USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID | XENOPORT, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7777070-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1919859-B1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID AND USE | XENOPORT INC (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20100036148-A1 | Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use | XENOPORT, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7592369-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080153898-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. | 2008-06-26 | — | — | US | disclosed |
| US-7351740-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070027210-A1 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060040-A1 | USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID | PIGS, CPS1, ACMSD | MMP1 1024/4885MMP2 313/4885MMP3 288/4885 |
| US-20070027210-A1 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | ACMSD, APEH, CPS1 | MMP1 551/4885MMP2 259/4885MMP3 527/4885 |
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | ACMSD, APEH, CPS1 | MMP1 551/4885MMP2 259/4885MMP3 527/4885 |
| US-20080153898-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | ACMSD, APEH, CPS1 | MMP1 551/4885MMP2 259/4885MMP3 527/4885 |
| US-20100036148-A1 | Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use | ACMSD, APEH, CPS1 | MMP1 551/4885MMP2 259/4885MMP3 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.